Results 1 to 10 of about 43,858 (197)

Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?

Current Therapeutic Research, 2021
: Background: Concerns have been raised that the risk of severe acute respiratory syndrome coronavirus 2 infection, or more severe or critical coronavirus disease 2019 (COVID-19), may be higher in immunocompromised individuals receiving immunomodulatory
Samantha Howland, MPharm, J. Jasper Deuring, PhD, Xiaofeng Zhou, PhD, Yan Chen, MD, PhD, Licia MH Mota, MD, Ryan C. Ungaro, MD, MS   +5 more
doaj   +1 more source

Tofacitinib is not a biologic

Annals of Gastroenterology, 2016
As the Global Medical Aff airs Gastroenterology Lead for tofacitinib at Pfi zer, I read with great interest the review by Dr Ungar and Dr Kopylov entitled “Advances in the development of new biologics in infl ammatory bowel disease (IBD)” [1]. In reading the article, I identifi ed a number of inaccuracies concerning tofacitinib, which I thought should ...
openaire   +2 more sources

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis

Arthritis Research & Therapy
Background Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Time to improvement in core domains of AS was estimated in tofacitinib-treated patients with AS. Methods This post hoc analysis used phase 3 trial data
Victoria Navarro-Compán, Atul Deodhar, Rachid Bahiri, Andrew G. Bushmakin, Joseph C. Cappelleri, Jihane Rammaoui   +5 more
doaj   +1 more source

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response

Frontiers in Immunology, 2021
ObjectiveCurrent knowledge on the actions of tofacitinib on cytokine signaling pathways in rheumatoid arthritis (RA) is based on in vitro studies. Our study is the first to examine the effects of tofacitinib treatment on Janus kinase (JAK) - signal ...
Maaria Palmroth, Krista Kuuliala, Ritva Peltomaa, Anniina Virtanen, Antti Kuuliala, Antti Kurttila, Anna Kinnunen, Marjatta Leirisalo-Repo, Olli Silvennoinen, Olli Silvennoinen, Olli Silvennoinen, Pia Isomäki, Pia Isomäki   +12 more
doaj   +1 more source

Effect of P. corylifolia on the pharmacokinetic profile of tofacitinib and the underlying mechanism

Frontiers in Pharmacology
This work aimed to explore the mechanisms underlying the interaction of the active furanocoumarins in P. corylifolia on tofacitinib both in vivo and in vitro. The concentration of tofacitinib and its metabolite M8 was determined using UPLC-MS/MS.
Yu Wang, Quan Zhou, Huihui Wang, Wei Song, Jianfeng Wang, Abdullah Al Mamun, Peiwu Geng, Yunfang Zhou, Shuanghu Wang   +8 more
doaj   +1 more source

Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis

Mediators of Inflammation, 2019
Objective. Tofacitinib is a novel therapy for rheumatoid arthritis (RA). The aim of this study was to measure various serum cytokines levels and to explore potential markers predictive of therapeutic efficacy of tofacitinib for RA patients.
Yuxuan Li, Lin Yuan, Jie Yang, Yue Lei, Hui Zhang, Liping Xia, Hui Shen, Jing Lu   +7 more
doaj   +1 more source

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

ACR Open Rheumatology, 2021
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease ...
Joel M. Kremer, Clifton O. Bingham III, Laura C. Cappelli, Jeffrey D. Greenberg, Ann M. Madsen, Jamie Geier, Jose L. Rivas, Alina M. Onofrei, Christine J. Barr, Dimitrios A. Pappas, Heather J. Litman, Kimberly J. Dandreo, Andrea B. Shapiro, Carol A. Connell, Arthur Kavanaugh   +14 more
doaj   +1 more source

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis

Rheumatology and Therapy, 2023
Introduction Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Using mediation modelling, we describe interrelationships between fatigue, pain, morning stiffness, C-reactive protein (CRP) and tofacitinib ...
Lars Erik Kristensen, Victoria Navarro-Compán, Marina Magrey, Andrew G. Bushmakin, Joseph C. Cappelleri, Arne Yndestad, Oluwaseyi Dina, Peter C. Taylor   +7 more
doaj   +1 more source

Synthesis and evaluation of hydrogen peroxide sensitive tofacitinib prodrugs

European Journal of Medicinal Chemistry Reports, 2022
Tofacitinib (CP-690,550), an approved Janus kinase (JAK) inhibitor, has been proven highly efficacious in treating rheumatoid arthritis (RA). Unfortunately, tofacitinib's clinical application has been limited by adverse side effects that arise from its ...
Viola Previtali, Ulrik Bering Keiding, Asger Hegelund Olsen, Jorge Peiró Cadahía, Anne Skovsbo Clausen, Andreas Kjaer, Thomas Lars Andresen, Anders Elias Hansen, Mads Hartvig Clausen   +8 more
doaj   +1 more source

Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. [PDF]

PLoS ONE, 2017
We evaluated the efficacy and safety of tofacitinib in patients with rheumatoid arthritis (RA) in a real-world setting.Seventy consecutive patients, for whom tofacitinib was initiated between November 2013 and May 2016, were enrolled.
Naoki Iwamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Shoichi Fukui, Masataka Umeda, Ayako Nishino, Yoshiro Horai, Tomohiro Koga, Shin-Ya Kawashiri, Toshiyuki Aramaki, Kunihiro Ichinose, Yasuko Hirai, Mami Tamai, Hideki Nakamura, Kaoru Terada, Tomoki Origuchi, Katsumi Eguchi, Yukitaka Ueki, Atsushi Kawakami   +19 more
doaj   +1 more source